How to Cite
Abstract
Prostate cancer is one of the most prevalent in the world and affects many men. There are screening methods which are dedicated to carrying out earlier detection and thus reducing mortality, over the years an attempt has been made to create new screening methods, but the most prevalent and functional ones continue to be the digital rectal examination and the prostate specific antigen. Although of course all have their disadvantages, and this is what has been tried to improve. In many cases, the patient does not present symptoms until it is very late, so it is important to recognize them in time. There are different treatment methods that depend on whether we have localized cancer or already metastasized.
Keywords
References
Ramos C, Juan F, Mercado A. Detección precoz de cáncer de próstata: controversias y recomendaciones actuales. REV MED CLIN CONDES. 2018;2:128-35.
Acosta N, Varela R, Mesa JA, Serrano Lopez M, Lucía Combita A, Sanabria-Salas MC. Biomarcadores de pronóstico en pacientes con cáncer de próstata localizado. Rev Colomb Cancerol. 2017;2:113-25.
Savón L. Cáncer de próstata: actualización. Revista Información Científica. 2019;98(1):118-126.
Merriel S, Funston G, Hamilton W. Prostate Cancer in Primary Care. Adv Ther. 2018;1285-94.
Datos y Estadísticas sobre el Cáncer entre los Hispanos/Latinos 2018-2020. Sociedad Americana contra el Cáncer; 2020.
Delgado D. Cáncer de próstata: etiología, diagnóstico y tratamiento. Revista Medica de Costa Rica y Centroamerica. 2016; 707-710.
Veiby H, Dahl AA, Harald O, Fosså S. Modern treatment of metastatic prostate cancer. Tidsskr Nor Legeforen. 2017;11:803-6.
Wang G, Zhao D, Spring D, DePinho R. Genetics and biology of prostate cancer. GENES & DEVELOPMENT. 2021;1105-40.
Davila C. Prostate cancer between prognosis and adequate/proper therapy. Journal of Medicine and Life. 2017;10(1):5-12.
Matsushita M, Fujita K, Nonomura N. Influence of Diet and Nutrition on Prostate Cancer. Int J Mol Sci. 2020;1-18.
Ritch C, Cookson M. Recent trends in the management of advanced prostate cancer. F1000 Faculty Rev. 21 de septiembre de 2018;1-7.
Vlachaki A, Baltogiannis D, Batistatou A, Tsambalas S, Simos Y, Palatianou M, et al. Screening for prostate cancer: moving forward in the molecular era. JBUON. 2018;5.
Ferro M, Buonerba C, Terracciano D, Lucarelli G, Cosimato V, Bottero D, et al. Biomarkers in localized prostate cancer. Future Oncol. 2016;3:399-411.
Catalona W. Prostate Cancer Screening. 102. 2018;2:199-214.
Gamat M, McNeel D. Androgen deprivation and immunotherapy for the treatment of prostate cancer. Endocr Relat Cancer.
;12:T297-310.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2021 Array